104 related articles for article (PubMed ID: 38723115)
1. Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review.
Turjap M; Pelcová M; Gregorová J; Šmak P; Martin H; Štingl J; Peš O; Juřica J
Ther Drug Monit; 2024 Jun; 46(3):321-331. PubMed ID: 38723115
[TBL] [Abstract][Full Text] [Related]
2. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Brotelle T; Bay JO
Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
[TBL] [Abstract][Full Text] [Related]
4. Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer.
Tanaka H; Hiraga H; Takekuma Y; Harabayashi T; Nagamori S; Endo M; Sugawara M
Biol Pharm Bull; 2020 May; 43(5):762-766. PubMed ID: 32115446
[TBL] [Abstract][Full Text] [Related]
5. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
6. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.
Suttle AB; Ball HA; Molimard M; Hutson TE; Carpenter C; Rajagopalan D; Lin Y; Swann S; Amado R; Pandite L
Br J Cancer; 2014 Nov; 111(10):1909-16. PubMed ID: 25349968
[TBL] [Abstract][Full Text] [Related]
7. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma.
Méndez-Vidal MJ; Molina Á; Anido U; Chirivella I; Etxaniz O; Fernández-Parra E; Guix M; Hernández C; Lambea J; Montesa Á; Pinto Á; Ros S; Gallardo E
BMC Pharmacol Toxicol; 2018 Nov; 19(1):77. PubMed ID: 30477570
[TBL] [Abstract][Full Text] [Related]
8. Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients.
Westerdijk K; Krens SD; Steeghs N; van der Graaf WTA; Tjwa ETTL; Westdorp H; Desar IME; van Erp NP
Cancer Chemother Pharmacol; 2024 Apr; 93(4):353-364. PubMed ID: 38104304
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Pazopanib on the Cardiovascular System.
Justice CN; Derbala MH; Baich TM; Kempton AN; Guo AS; Ho TH; Smith SA
J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):387-398. PubMed ID: 29706106
[TBL] [Abstract][Full Text] [Related]
10. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
[TBL] [Abstract][Full Text] [Related]
11. [Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].
Gennigens C; Jerusalem G
Rev Med Liege; 2012; 67(7-8):437-42. PubMed ID: 22984765
[TBL] [Abstract][Full Text] [Related]
12. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
[TBL] [Abstract][Full Text] [Related]
13. Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.
Verheijen RB; Swart LE; Beijnen JH; Schellens JHM; Huitema ADR; Steeghs N
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1171-1178. PubMed ID: 29051995
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma.
Sternberg CN; Donskov F; Haas NB; Doehn C; Russo P; Elmeliegy M; Baneyx G; Banerjee H; Aimone P; Motzer RJ
Clin Cancer Res; 2018 Jul; 24(13):3005-3013. PubMed ID: 29330204
[No Abstract] [Full Text] [Related]
15. Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?
Erdogan B; Kostek O; Bekir Hacioglu M; Gokyer A; Kucukarda A; Ozcan E; Gokmen I; Uzunoglu S; Cicin I
J BUON; 2021; 26(5):2196-2201. PubMed ID: 34761635
[TBL] [Abstract][Full Text] [Related]
16. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).
Schmidinger M; Bamias A; Procopio G; Hawkins R; Sanchez AR; Vázquez S; Srihari N; Kalofonos H; Bono P; Pisal CB; Hirschberg Y; Dezzani L; Ahmad Q; Jonasch E;
Oncologist; 2019 Apr; 24(4):491-497. PubMed ID: 30867244
[TBL] [Abstract][Full Text] [Related]
17. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
[TBL] [Abstract][Full Text] [Related]
18. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.
Topal A; Sayın S; Gokyer A; Kucukarda A; Kostek O; Bekir Hacıoglu M; Uzunoglu S; Erdogan B; Cicin I
J BUON; 2021; 26(4):1628-1634. PubMed ID: 34565028
[TBL] [Abstract][Full Text] [Related]
19. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.
Tannir NM; Msaouel P; Ross JA; Devine CE; Chandramohan A; Gonzalez GMN; Wang X; Wang J; Corn PG; Lim ZD; Pruitt L; Karam JA; Wood CG; Zurita AJ
Eur Urol Oncol; 2020 Oct; 3(5):687-694. PubMed ID: 31272939
[TBL] [Abstract][Full Text] [Related]
20. Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database.
Hackshaw MD; Nagar SP; Parks DC; Miller LA
J Manag Care Spec Pharm; 2014 Jun; 20(6):603-10. PubMed ID: 24856598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
